Protective effects of Baibu Tang on bleomycin-induced pulmonary fibrosis in mice

被引：4

作者：

Xie Weina ^{[1
]}

Ding Qi ^{[1
]}

Sun Jing ^{[1
]}

Zhang Chaofeng ^{[1
]}

Zhang Mian ^{[1
]}

Xu Xianghong ^{[1
]}

机构：

[1] China Pharmaceut Univ, Coll Tradit Chinese Med, Nanjing 211198, Jiangsu, Peoples R China

来源：

JOURNAL OF CHINA PHARMACEUTICAL UNIVERSITY | 2018年 / 49卷 / 04期

关键词：

Baibu Tang; Neotuberostemonine; Pulmonary fibrosis; Stemoninine; Tuberostemonine;

D O I：

10.11665/j.issn.1000-5048.20180415

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

This study aimed to investigate the protective effects of Baibu Tang on bleomycin-induced pulmonary fibrosis in mice. After intratracheally giving bleomycin (3.5 mg/kg), mice were orally administered Baibu Tang once a day for 14 consecutive days, takingnintedanib as a positive control. The anti-fibrotic effects were assessed by the hydroxyproline level and the histopathological changes in H&E or Masson stained lung tissues. The results revealed that the lung coefficient, hydroxyproline content, inflammation and collagen deposition were increased significantly in the lung tissue of the model mice. Both ethanol and water extracts of Baibu Tang significantly improved all the pathological indexes in mice, but the effect of the ethanol extract was better than that of the water extract. Baibu Tang with Baibu (root of Stemona tuberosa) containing different components (neotuberostemonine, tuberostemonine and stemoninine, respectively) could significantly reduce hydroxyproline level and collagen deposition in the lung tissue of bleomycin-induced mice, and there was no significant difference in their activity. This result showed that the changes in the chemical composition of Stemona tuberosa (Baibu, monarch drug for Baibu Tang) have little effect on the anti-fibrosis activity of Baibu Tang, and its mechanism and material basis need further investigation.

引用

页码：483 / 489

页数：7

共 16 条

[1] Liang J.R., Zhang Y.L., Xie T., Et al., Hyaluronan and tlr4 promote surfactant protein c-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice[J], Nat Med, 22, 11, pp. 1285-1293, (2016)
[2] Park S., Lee E.J., Recent advances in idiopathic pulmonary fibrosis [j]. Tubero, Rapir Dis (Seoul, 74, 1, pp. 1-6, (2013)
[3] Divya T., Dineshbabu V., Soumyakrishnan S., Et al., Celastro! enhances nrf2 mediated antioxidant enzymes and exhibits anti-fibrotic effect through regulation of collagen production against bleomycin-induced pulmonary fibrosis [J], Chem Biol Interact, 246, pp. 52-62, (2016)
[4] Hillary L.K., Flaherty K.R., Moore B.B., Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis[j]. Curr, Opin Pharmacol, 13, 3, pp. 377-385, (2013)
[5] Spagnolo P., Maher T.M., Richeldi L., Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy [j], Pharmacol Therapeut, 152, pp. 18-27, (2015)
[6] Yang L., Lv X.D., Liu Y.M., Et al., Research progress on the mechanism of oxidative stress in traditional Chinese medicine on prevention and treatment of pulmonary fibrosis [J], World J Integr Tradit West Med, 12, 3, pp. 297-300, (2017)
[7] Pharmacopoeia of the People' S Republic of China, 1, (2015)
[8] Wang Z.W., Yang P.L., Shen L., Et al., Clinical study of baibu yang-fei decocted extract in the treatment for COPD patients at stable stage[j], Vest J Tradii Chin Med, 28, 5, pp. 56-59, (2015)
[9] Li R., Zhang Y., Chen Y.R., Clinical analysis of 38 cases of pulmonary fibrosis treated by tonifying kidney and activating meridians [J], J Mod Clin Med, 40, 4, pp. 285-287, (2014)
[10] Xu Y.T., Hon P.M., Jiang R.W., Et al., Antitussive effects of stemona tuberosa with different chemical profiles[j], J Ethnopharmacol, 108, 1, pp. 46-53, (2006)

← 1 2 →